First-line therapy for CLL: options abound.

First-line therapy for chronic lymphocytic leukaemia (CLL) is rapidly evolving, with a recent phase III trial showing that fixed-duration therapy with BCL-2 inhibitor-based doublet regimens is non-inferior to continuous BTK inhibitor therapy. Novel approaches to further improve outcomes with time-limited regimens include measurable residual disease-guided and three-drug approaches.